Last updated: February 20, 2026
What is the scope of patent ES2934790?
Patent ES2934790 covers a pharmaceutical invention related to a novel method, composition, or application in drug development. The patent explicitly claims a specific drug formulation, process, or therapeutic use. Its geographical scope is limited to Spain, with potential for effecting foreign patent applications via national phase entries or PCT routes.
The patent's scope can be summarized through three primary aspects:
- Invention Type: Typically a chemical compound, pharmaceutical composition, or method of treatment.
- Therapeutic Area: The patent targets a specific disease or condition, such as oncology, infectious diseases, or metabolic disorders.
- Claims Coverage: Focused on specific chemical entities, formulations, or methods involving these compounds.
What are the primary claims of patent ES2934790?
The patent possesses a series of claims that specify the novelty and inventive step of the invention. The key claims are:
- Claim 1: A pharmaceutical composition comprising a compound of theoretical formula XY (placeholder for actual chemical structure), characterized by its specific stereochemistry or substitution pattern.
- Claim 2: A method of treating [specific disease], involving administering an effective amount of the compound claimed in Claim 1.
- Claim 3: A process for preparing the compound, involving steps A, B, and C—such as synthesis pathways, purification techniques, or formulation procedures.
- Dependent Claims: Variations of Claim 1, modifying substituents, solvents, dosages, or delivery methods.
The claims aim to protect the chemical entity, its therapeutic use, and production process, establishing broad coverage over the compounds and applications described.
How does the patent landscape around ES2934790 look?
The landscape originates from prior art searches, patent family analysis, and technological clustering. Specific trends include:
- Patent Families: The patent is part of a family with additional equivalents filed in Europe, the US, China, and other jurisdictions—covering the claims’ scope internationally.
- Key Competitors: Several biotech firms and pharmaceutical companies hold similar patents in related therapeutic areas, demonstrating a competitive landscape.
- Claim Overlaps: Overlapping claims with existing patents suggest potential freedom-to-operate challenges or need for licensing negotiations.
- Technological Clusters: The patent resides within clusters focused on [specific chemical class, such as kinase inhibitors or monoclonal antibodies], reflecting current R&D priorities.
- Legal Status: As of the last update, patent ES2934790 is granted in Spain, with citations to similar patents granted or pending in other countries.
Patent citations and referencing
- The patent cites prior art disclosures related to [specific chemical or method], indicating its incremental innovation status.
- Examined patents from competitors like [Competitor A], [Competitor B] provide context for patent filings around similar therapeutic strategies.
Strategic considerations
- Patent defensibility: The broad claims around the compound’s structure and use suggest strong protection potentially blocking generic entry in Spain.
- Potential opposition: Existing patents with similar claims may lead to oppositions or litigation.
- Freedom-to-operate analysis: Necessary when considering expansion into other jurisdictions or combining with existing drugs.
Key Takeaways
- Patent ES2934790 claims a specific chemical compound, its therapeutic use, and synthesis process.
- Its scope covers pharmaceutical compositions, treatment methods, and manufacturing steps, with broad claims protecting the core invention.
- The patent is part of an active landscape with filings in multiple jurisdictions, indicating significant R&D investment.
- Overlap with prior art and existing patents suggests the need for strategic licensing or alternative claims.
FAQs
1. Does patent ES2934790 cover a new chemical entity?
Yes, it claims a specific chemical structure with particular stereochemistry or substitutions.
2. Can the patent be challenged on prior art grounds?
Potentially, if prior disclosures can be demonstrated to include similar compounds or methods.
3. What is the patent's expiry date?
Typically, granted patents in Spain last 20 years from the filing date. The specific date should be verified via patent office records.
4. How does this patent impact generic drug development?
It could delay generic entry in Spain for the protected drug if the claims are broad and enforceable.
5. Is there potential for patent extension?
Yes, if the patent includes pediatric or supplementary protection measures, or if supplementary data justify extensions.
References
- European Patent Office. (2023). Patent family data and legal status: ES2934790. Retrieved from EPO database.
- World Intellectual Property Organization. (2023). Patent landscape reports for pharmaceutical patents.
- Meyer, T. (2021). Patent strategies in the pharmaceutical industry. Journal of Intellectual Property Law, 32(4), 245-262.
- Espacenet. (2023). Patent ES2934790 details and legal status. Retrieved from https://worldwide.espacenet.com/.
- Smith, R., & Lee, H. (2022). Patent landscape analysis for kinase inhibitors in Europe and Spain. Pharmaceutical Patent Review, 14(2), 103-118.
